FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1966191179> ?p ?o ?g. }

• W1966191179 endingPage "2938" @default.
• W1966191179 startingPage "2932" @default.
• W1966191179 abstract "Background. The growth-inhibiting and differentiating effects of sodium phenylacetate against hematopoietic and solid tumor cell lines has aroused clinical interest in its use as an anticancer drug. In an earlier Phase I trial of phenylacetate aimed at maintaining serum drug concentrations in the range that proved active in vitro (>250 μg/ml) for 2 consecutive weeks, infusion rates approached the maximum velocity of drug elimination and commonly resulted in drug accumulation and reversible dose-limiting neurologic toxicity. In this study, the authors described the nonlinear pharmacokinetics, metabolism, toxicity, and clinical activity of phenylacetate. Methods. The treatment regimen of this Phase I study was designed to expose patients intermittently to drug concentrations exceeding 250 μg/ml and to allow time for drug elimination to occur between doses to minimize accumulation. Sodium phenylacetate was administered as a 1-hour infusion twice daily (8 a.m., 5 p.m.) at two dose levels of 125 and 150 mg/kg for a 2-week period. Therapy was repeated at 4-week intervals for patients who did not experience dose-limiting toxicity or disease progression. Results. Eighteen patients (4 of whom previously were treated with phenylacetate by continuous intravenous infusion) received 27 cycles of therapy. Detailed pharmacokinetic studies for eight patients indicated that phenylacetate induced its own clearance by a factor of 27% in a 2-week period. Dose-limiting toxicity, consisting of reversible central nervous system depression, was observed for three patients at the second dose level. One patient with refractory malignant glioma had a partial response, and one with hormone-independent prostate cancer achieved a 50% decline in prostate specific antigen level, which was maintained for 1 month. Conclusions. Phenylacetate administered at a dose of 125 mg/kg twice daily for 2 consecutive weeks is well tolerated. High grade gliomas and advanced prostate cancer are reasonable targets for Phase II clinical trials. Cancer 1995;75:2932–8." @default.
• W1966191179 created "2016-06-24" @default.
• W1966191179 creator A5001321994 @default.
• W1966191179 creator A5008079630 @default.
• W1966191179 creator A5019216062 @default.
• W1966191179 creator A5024024043 @default.
• W1966191179 creator A5027771391 @default.
• W1966191179 creator A5035326139 @default.
• W1966191179 creator A5036730232 @default.
• W1966191179 creator A5036782721 @default.
• W1966191179 creator A5064287156 @default.
• W1966191179 creator A5065139905 @default.
• W1966191179 date "1995-06-15" @default.
• W1966191179 modified "2023-10-16" @default.
• W1966191179 title "Phase I study of phenylacetate administered twice daily to patients with cancer" @default.
• W1966191179 cites W11097077 @default.
• W1966191179 cites W1487338389 @default.
• W1966191179 cites W160617378 @default.
• W1966191179 cites W191328410 @default.
• W1966191179 cites W1969482311 @default.
• W1966191179 cites W1976756918 @default.
• W1966191179 cites W1982734834 @default.
• W1966191179 cites W2013608017 @default.
• W1966191179 cites W2015092881 @default.
• W1966191179 cites W2021686285 @default.
• W1966191179 cites W2027643853 @default.
• W1966191179 cites W2048158170 @default.
• W1966191179 cites W2070075606 @default.
• W1966191179 cites W2070288036 @default.
• W1966191179 cites W2137529804 @default.
• W1966191179 cites W2149637946 @default.
• W1966191179 cites W2167805334 @default.
• W1966191179 cites W2273510854 @default.
• W1966191179 cites W2411999747 @default.
• W1966191179 doi "https://doi.org/10.1002/1097-0142(19950615)75:12<2932::aid-cncr2820751221>3.0.co;2-p" @default.
• W1966191179 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7773944" @default.
• W1966191179 hasPublicationYear "1995" @default.
• W1966191179 type Work @default.
• W1966191179 sameAs 1966191179 @default.
• W1966191179 citedByCount "115" @default.
• W1966191179 countsByYear W19661911792012 @default.
• W1966191179 countsByYear W19661911792013 @default.
• W1966191179 countsByYear W19661911792014 @default.
• W1966191179 countsByYear W19661911792015 @default.
• W1966191179 countsByYear W19661911792016 @default.
• W1966191179 countsByYear W19661911792017 @default.
• W1966191179 countsByYear W19661911792018 @default.
• W1966191179 countsByYear W19661911792019 @default.
• W1966191179 countsByYear W19661911792020 @default.
• W1966191179 countsByYear W19661911792021 @default.
• W1966191179 countsByYear W19661911792022 @default.
• W1966191179 countsByYear W19661911792023 @default.
• W1966191179 crossrefType "journal-article" @default.
• W1966191179 hasAuthorship W1966191179A5001321994 @default.
• W1966191179 hasAuthorship W1966191179A5008079630 @default.
• W1966191179 hasAuthorship W1966191179A5019216062 @default.
• W1966191179 hasAuthorship W1966191179A5024024043 @default.
• W1966191179 hasAuthorship W1966191179A5027771391 @default.
• W1966191179 hasAuthorship W1966191179A5035326139 @default.
• W1966191179 hasAuthorship W1966191179A5036730232 @default.
• W1966191179 hasAuthorship W1966191179A5036782721 @default.
• W1966191179 hasAuthorship W1966191179A5064287156 @default.
• W1966191179 hasAuthorship W1966191179A5065139905 @default.
• W1966191179 hasBestOaLocation W19661911791 @default.
• W1966191179 hasConcept C112705442 @default.
• W1966191179 hasConcept C121332964 @default.
• W1966191179 hasConcept C126322002 @default.
• W1966191179 hasConcept C142424586 @default.
• W1966191179 hasConcept C185592680 @default.
• W1966191179 hasConcept C2776897752 @default.
• W1966191179 hasConcept C2781413609 @default.
• W1966191179 hasConcept C29730261 @default.
• W1966191179 hasConcept C31760486 @default.
• W1966191179 hasConcept C55493867 @default.
• W1966191179 hasConcept C71924100 @default.
• W1966191179 hasConcept C87355193 @default.
• W1966191179 hasConcept C98274493 @default.
• W1966191179 hasConceptScore W1966191179C112705442 @default.
• W1966191179 hasConceptScore W1966191179C121332964 @default.
• W1966191179 hasConceptScore W1966191179C126322002 @default.
• W1966191179 hasConceptScore W1966191179C142424586 @default.
• W1966191179 hasConceptScore W1966191179C185592680 @default.
• W1966191179 hasConceptScore W1966191179C2776897752 @default.
• W1966191179 hasConceptScore W1966191179C2781413609 @default.
• W1966191179 hasConceptScore W1966191179C29730261 @default.
• W1966191179 hasConceptScore W1966191179C31760486 @default.
• W1966191179 hasConceptScore W1966191179C55493867 @default.
• W1966191179 hasConceptScore W1966191179C71924100 @default.
• W1966191179 hasConceptScore W1966191179C87355193 @default.
• W1966191179 hasConceptScore W1966191179C98274493 @default.
• W1966191179 hasIssue "12" @default.
• W1966191179 hasLocation W19661911791 @default.
• W1966191179 hasLocation W19661911792 @default.
• W1966191179 hasOpenAccess W1966191179 @default.
• W1966191179 hasPrimaryLocation W19661911791 @default.
• W1966191179 hasRelatedWork W1957709604 @default.
• W1966191179 hasRelatedWork W1995586676 @default.
• W1966191179 hasRelatedWork W2074629895 @default.

• next